Labcorp (LH) Projected to Post Earnings on Tuesday

Labcorp (NYSE:LH) is expected to be announcing its Q4 2025 results before the market opens on Tuesday, February 17th. Analysts expect the company to announce earnings of $3.95 per share and revenue of $3.5597 billion for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Tuesday, February 17, 2026 at 9:00 AM ET.

Labcorp Trading Down 1.0%

LH opened at $274.30 on Tuesday. Labcorp has a twelve month low of $209.38 and a twelve month high of $293.72. The company has a fifty day moving average of $261.92 and a 200-day moving average of $268.06. The stock has a market cap of $22.74 billion, a PE ratio of 26.95, a price-to-earnings-growth ratio of 1.75 and a beta of 1.03. The company has a quick ratio of 1.35, a current ratio of 1.55 and a debt-to-equity ratio of 0.59.

Labcorp Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, March 12th. Shareholders of record on Friday, February 27th will be given a dividend of $0.72 per share. The ex-dividend date of this dividend is Friday, February 27th. This represents a $2.88 dividend on an annualized basis and a yield of 1.0%. Labcorp’s dividend payout ratio is 28.29%.

Institutional Trading of Labcorp

Hedge funds and other institutional investors have recently bought and sold shares of the business. JPL Wealth Management LLC bought a new position in shares of Labcorp in the third quarter valued at $28,000. Headlands Technologies LLC raised its holdings in shares of Labcorp by 300.0% in the 2nd quarter. Headlands Technologies LLC now owns 128 shares of the medical research company’s stock worth $34,000 after acquiring an additional 96 shares during the last quarter. Larson Financial Group LLC lifted its position in Labcorp by 37.5% in the 3rd quarter. Larson Financial Group LLC now owns 154 shares of the medical research company’s stock valued at $44,000 after acquiring an additional 42 shares in the last quarter. MUFG Securities EMEA plc acquired a new position in Labcorp during the 2nd quarter valued at about $65,000. Finally, Geneos Wealth Management Inc. increased its holdings in Labcorp by 61.6% during the 2nd quarter. Geneos Wealth Management Inc. now owns 286 shares of the medical research company’s stock worth $75,000 after purchasing an additional 109 shares in the last quarter. Institutional investors own 95.94% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently weighed in on the company. JPMorgan Chase & Co. lifted their price objective on Labcorp from $317.00 to $319.00 and gave the stock an “overweight” rating in a research report on Friday. Robert W. Baird set a $313.00 target price on Labcorp in a report on Wednesday, January 14th. Truist Financial set a $320.00 price target on Labcorp in a research note on Tuesday, October 14th. UBS Group reduced their price objective on shares of Labcorp from $325.00 to $320.00 and set a “buy” rating for the company in a research report on Wednesday, October 29th. Finally, Wall Street Zen upgraded shares of Labcorp from a “hold” rating to a “buy” rating in a research note on Friday, January 23rd. Nine investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $300.75.

Labcorp Company Profile

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.